X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse VENUS REMEDIES with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   ADCOCK INGRAM
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
ADCOCK INGRAM
Jun-14
VENUS REMEDIES/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs218350-   
Low Rs82253-   
Sales per share (Unadj.) Rs365.6104.2-  
Earnings per share (Unadj.) Rs1.5-26.2-  
Cash flow per share (Unadj.) Rs37.9-21.8-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs382.581.8-  
Shares outstanding (eoy) m11.44168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.42.9 14.2%   
Avg P/E ratio x101.0-11.5 -879.4%  
P/CF ratio (eoy) x4.0-13.9 -28.6%  
Price / Book Value ratio x0.43.7 10.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,71750,869 3.4%   
No. of employees `0001.04.3 23.8%   
Total wages/salary Rs m3243,193 10.2%   
Avg. sales/employee Rs Th4,100.74,095.3 100.1%   
Avg. wages/employee Rs Th318.0743.7 42.8%   
Avg. net profit/employee Rs Th16.7-1,031.9 -1.6%   
INCOME DATA
Net Sales Rs m4,18317,581 23.8%  
Other income Rs m20123 16.3%   
Total revenues Rs m4,20317,704 23.7%   
Gross profit Rs m812-3,047 -26.6%  
Depreciation Rs m417759 54.9%   
Interest Rs m380476 79.8%   
Profit before tax Rs m35-4,159 -0.8%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m18260 7.0%   
Profit after tax Rs m17-4,430 -0.4%  
Gross profit margin %19.4-17.3 -112.0%  
Effective tax rate %51.6-6.2 -825.3%   
Net profit margin %0.4-25.2 -1.6%  
BALANCE SHEET DATA
Current assets Rs m2,77112,877 21.5%   
Current liabilities Rs m1,9317,245 26.7%   
Net working cap to sales %20.132.0 62.6%  
Current ratio x1.41.8 80.7%  
Inventory Days Days125111 112.7%  
Debtors Days Days54124 43.4%  
Net fixed assets Rs m5,3287,506 71.0%   
Share capital Rs m11482 140.1%   
"Free" reserves Rs m4,1770-   
Net worth Rs m4,37613,799 31.7%   
Long term debt Rs m1,9114,849 39.4%   
Total assets Rs m8,42826,068 32.3%  
Interest coverage x1.1-7.7 -14.1%   
Debt to equity ratio x0.40.4 124.2%  
Sales to assets ratio x0.50.7 73.6%   
Return on assets %4.7-15.2 -31.0%  
Return on equity %0.4-32.1 -1.2%  
Return on capital %6.6-19.8 -33.3%  
Exports to sales %00-   
Imports to sales %20.50-   
Net fx Rs m-8580-   
CASH FLOW
From Operations Rs m4691,501 31.2%  
From Investments Rs m29-461 -6.3%  
From Financial Activity Rs m-4644,401 -10.5%  
Net Cashflow Rs m355,441 0.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.83 Rs / ZAR

Compare VENUS REMEDIES With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: DR. REDDYS LAB  LUPIN LTD  GLENMARK PHARMA  PANACEA BIOTECH  SUVEN LIFE  



Today's Market

Share Markets in India End Flat; Dr Reddy's & Tata Steel Top Gainers(Closing)

Indian share markets continued to trade range bound in afternoon session with market participants awaiting the US Federal Reserve's policy statement.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

180,000%: The Returns That Could Have Been(The 5 Minute Wrapup)

Sep 7, 2017

For successful investing in small caps, it's important to know when not to press the panic button.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 20, 2017 03:36 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS